Reviewing Adamas Pharmaceuticals (ADMS) & CASI Pharmaceuticals (CASI)
Adamas Pharmaceuticals (NASDAQ: ADMS) and CASI Pharmaceuticals (NASDAQ:CASI) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.
Insider & Institutional Ownership
72.0% of Adamas Pharmaceuticals shares are held by institutional investors. Comparatively, 3.4% of CASI Pharmaceuticals shares are held by institutional investors. 29.0% of Adamas Pharmaceuticals shares are held by insiders. Comparatively, 13.0% of CASI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk and Volatility
Adamas Pharmaceuticals has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.
This table compares Adamas Pharmaceuticals and CASI Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Adamas Pharmaceuticals and CASI Pharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Adamas Pharmaceuticals||$570,000.00||1,119.02||-$60.05 million||($3.37)||-8.31|
|CASI Pharmaceuticals||$50,000.00||3,230.31||-$9.45 million||($0.15)||-15.80|
CASI Pharmaceuticals has higher revenue, but lower earnings than Adamas Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Adamas Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings and price targets for Adamas Pharmaceuticals and CASI Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Adamas Pharmaceuticals presently has a consensus price target of $39.50, indicating a potential upside of 41.07%. CASI Pharmaceuticals has a consensus price target of $3.00, indicating a potential upside of 26.58%. Given Adamas Pharmaceuticals’ higher possible upside, equities research analysts clearly believe Adamas Pharmaceuticals is more favorable than CASI Pharmaceuticals.
CASI Pharmaceuticals beats Adamas Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).
Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.